Therapeutic Drug Monitoring · 2001 · 39 citations · 15 references
MedicinePharmacokineticsPharmacologyDrug InteractionsDrug MetabolismPharmacogeneticsDrug DependenceDrug DispositionDrug Metabolism GeneticsDrug ResponseDrug ToxicityCo-use Of Other DrugsCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2c19 PharmacogeneticsCyp450-mediated InteractionsPhenytoin TherapySelective Serotonin Reuptake Inhibitor TreatmentSelective Serotonin Reuptake Inhibitor Use
A patient had phenytoin intoxication after administration of fluvoxamine, a selective serotonin reuptake inhibitor. The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1). The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.
15
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Kim Brøsen, Erik Skjelbo, Birgitte Buur Rasmussen et al. · Biochemical Pharmacology · 1993 · 372 citations
Kohsuke Mamiya, Ichiro Ieiri, Junta Shimamoto et al. · Epilepsia · 1998 · 174 citations
LL von Moltke, DJ Greenblatt, MM Cotreau‐Bibbo et al. · British Journal of Clinical Pharmacology · 1994 · 161 citations · Full text
BB Rasmussen, Jukka Mäenpää, Olavi Pelkonen et al. · British Journal of Clinical Pharmacology · 1995 · 150 citations · Full text